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Background:  The present study investigates the efficacy in glycemic control by adding once-a-day glulisine to glargine as a basal 
plus regimen and factors influencing glycemic control with the basal plus regimen in Korean subjects with type 2 diabetes.
Methods:  In the present retrospective study, subjects previously treated with the basal plus regimens for at least 6 months were 
reviewed. Changes in glycemic profiles and clinical parameters were evaluated.
Results:  A total of 87 subjects were ultimately enrolled in this study. At baseline, mean glycated hemoglobin (A1c) and glycated 
albumin were 8.5% (8.0% to 9.6%) and 25.2±7.6%, respectively. After treatment with the basal plus regimen, patients had signifi-
cant reductions of A1c at 6 months (0.8±0.1%, P<0.001) and their postprandial glucose levels were decreased by 48.7±10.3 mg/
dL (P<0.001). Multiple logistic regression showed old age (odds ratio [OR], 1.25; 95% confidence interval [CI], 1.02 to 1.55), high 
initial A1c (OR, 22.21; 95% CI, 2.44 to 201.78), and lower amounts of glargine (OR, 0.85; 95% CI, 0.76 to 0.99), and glimepiride 
(OR, 0.23; 95% CI, 0.06 to 0.93) at baseline were independently associated with good responders whose A1c reduction was more 
than 0.5%.
Conclusion:  The authors suggest a basal plus regimen may be effective in reducing glucose levels of subjects with old age, high 
initial A1c, and patients on low doses of glimepiride and glargine. Despite the use of high doses of hypoglycemic agents, elderly 
patients with poorly-controlled diabetes are preferred for early initiation of the basal plus regimen.
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INTRODUCTION
 
Tight glycemic control, as close to the non-diabetic range as 
possible, without side effects from glucose-lowering agents, 
such as hypoglycemia, may prevent or delay micro- and mac-
ro-vascular complications in patients with type 2 diabetes mel-
litus (T2DM) [1-3]. If patients fail to achieve or sustain the tar-
get glycemic goal, individualized addition of oral anti-diabetic 
drugs (OADs) or initiation of basal insulin such as glargine or 
detemir with the aim of achieving a fasting blood glucose (AC) 
level of less than or equal to 100 mg/dL should be considered 
according to a consensus statement [4]. Accordingly, for the 
progressive decline in β-cell function in T2DM [5], basal insu-
lin-based combination of OADs or short-acting insulin is com-
monly initiated as a regimen for achieving or sustaining a gly-
cemic target [6]. Particularly in Korean subjects, the secretory 
dysfunction of β-cells is a major contributing factor to the de-
velopment and aggravation of hyperglycemia in T2DM [7-9]. 
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However, little information is currently available regarding the 
effects of adding once-a-day glulisine (rapid-acting insulin an-
alogue) to glargine as a basal plus regimen in Korean patients 
with T2DM. In addition, no evidence has been documented 
regarding the characteristics of Korean diabetic patients who 
responded satisfactorily to the basal plus regimen after failure 
of combination therapy with basal insulin and OADs. 
  Therefore, the present study analyzed the effects of the basal 
plus regimen, and the clinical and metabolic characteristics of 
T2DM patients who were inadequately controlled by the basal 
insulin-based therapy combined with OADs. The present 
study investigated the efficacy in glycemic control of the basal 
plus regimen and factors influencing glycemic control after 6 
months of using the basal plus regimen in Korean subjects 
with T2DM. 
METHODS
Patients and research design
In this retrospective study, T2DM patients who satisfied all of 
the following inclusion criteria were analyzed: 1) subjects reg-
istered in the Severance Hospital Diabetes Insulin Education 
Registry between January 2009 and September 2010; and 2) 
patients who recently added a once-daily dose of glulisine to 
basal glargine, a basal insulin analogue injection (basal plus 
regimen) during the study period. Subjects were excluded for 
any of the following reasons: subjects with 1) malignancy, 2) 
severe liver disease corresponding to Child-Pugh class C, 3) 
chronic kidney disease at stages 4 and 5 (estimated glomerular 
filtration rate of less than 30 mL/min per 1.73 m
2), 4) insulin 
regimen using more than twice daily administration of gluli-
sine during the study period, 5) discontinuance of the injection 
of glulisine or glargine, 6) pregnancy, and 7) admitted to the 
hospital during the study due to another disease. Registered 
patients received comprehensive education regarding self-man-
agement skills, self-monitoring of blood glucose levels, treat-
ment of hypoglycemia, insulin administration, and lifestyle 
modification at the Severance Diabetes Center. The study pro-
tocol was approved by the ethics committee of the Yonsei Uni-
versity College of Medicine.
  Changes in glycated hemoglobin (A1c) and glycated albu-
min (GA) at 3 and 6 months after initiation of the basal plus 
regimen were evaluated. Dose titrations and changes in con-
comitant OAD use were also analyzed. Davidson et al. [10] re-
ported that a 24-week-basal plus regimen decreased A1c levels 
by 0.45% in patients with T2DM who had failed with basal in-
sulin treatment. Based on this data, subjects with A1c reduc-
tion of more than 0.5% were considered as good responders. 
Ultimately enrolled subjects were classified into two groups 
according to change in basal A1c after 6 months of treatment 
(Group I, A1c reduction <0.5%; Group II, A1c reduction 
≥0.5%).
Laboratory measurements
A1c was measured by high performance liquid chromatogra-
phy using Variant II Turbo testing system (Bio-Rad Laborato-
ries, Hercules, CA, USA). Serum GA was determined by an 
enzymatic method using an albumin-specific proteinase, ke-
toamine oxidase, and albumin assay reagent (LUCICA GA-L; 
Asahi Kasei Pharma Co., Tokyo, Japan), as well as the Hitachi 
7699 P module autoanalyzer (Hitachi Instruments Service, 
Tokyo, Japan). Plasma glucose was measured using the glucose 
oxidase method. Plasma triglycerides (TG), total cholesterol, 
high density lipoprotein cholesterol (HDL-C), blood urea ni-
trogen (BUN), creatinine (Cr), aspartate aminotransferase 
(AST), and alanine aminotransferase (ALT) levels were as-
sayed using a routine Hitachi 7600 autoanalyzer (Hitachi In-
struments Service). Low density lipoprotein cholesterol (LDL-
C) was calculated using the Friedewald equation. Pancreatic 
β-cell secretory function was assessed according to 1) C-pep-
tide increment (∆C-peptide=postprandial C-peptide-fasting 
C-peptide) and 2) incline of C-peptide increment (∆C-pep-
tide/fasting C-peptide) [11].
Statistical analyses
All continuous variables were expressed as mean±standard 
deviation or median with the interquartile ranges, when vari-
ables were not normally distributed. Whether each variable 
was normally distributed using the Kolmogorov-Smirnov test 
was examined. The Student’s t-test, Mann-Whitney U test, 
Pearson’s chi-square test, and multiple logistic regression anal-
ysis were performed to assess the association between respon-
siveness to the basal plus regimen and various clinical and lab-
oratory parameters, as appropriate. Changes in A1c, GA, AC, 
and postprandial glucose (PC) at 3 and 6 months after initia-
tion of the basal plus regimen were compared using a paired t-
test with the Bonferroni procedure for multiple comparisons. 
Since A1c, as well as doses of glulisine, glimepiride and met-
formin showed non-normality based on the Kolmogorov-
Smirnov test, the Wilcoxon signed rank test was used to test 232
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those variables. The data was analyzed using two sided P val-
ues, and a P value less than 0.05 (0.025 in paired t-test with 
Bonferroni correction) was considered to be statistically sig-
nificant. All statistical analyses were conducted using the SPSS 
software for Windows version 18.0 (SPSS Inc., Chicago, IL, 
USA).
RESULTS
Among 124 Korean type 2 diabetic subjects who satisfied the 
inclusion criteria, 37 subjects were excluded because 14 sub-
jects used rapid-acting insulin more than twice a day, 13 pa-
tients discontinued glulisine injection, and 10 patients were 
admitted to the hospital. Ultimately, 87 patients (50 men, 37 
women) were enrolled in the present study.
Clinical and laboratory characteristics of patients at 
baseline
The patients’ demographic and clinical characteristics are 
summarized in Table 1. Mean age and duration of diabetes 
Table 1. Demographic and clinical parameters of the study population
Parameter Total (n=87) Group I (n=37) Group II (n=50) P value
Age, yr 63.2±9.8 60.4±9.4 65.2±9.6 0.021
Gender, M/F 50/37 25/12 25/25 0.101
BMI, kg/m
2 25.6±4.0 25.3±3.9 25.8±4.1 0.612
Duration of diabetes, yr 14.8±9.4 11.9±7.7 16.9±10.0 0.010
Laboratory profiles
A1c, % 8.5 (8.0-9.6) 8.0 (7.8-8.3) 9.0 (8.3-10.1) <0.001
GA, % (n=66) 25.2±7.6 22.5±7.2 27.1±7.3 0.015
AC, mg/dL 129.5±54.3 130.8±67.9 128.5±42.2 0.848
PC, mg/dL 257.3±85.7 264.2±106.2 252.2±67.6 0.539
Total cholesterol, mg/dL 160.3±38.1 166.8±40.9 155.6±35.6 0.405
HDL-C, mg/dL 43.0±10.9 42.4±10.8 43.5±1.0 0.816
LDL-C, mg/dL 83.3±3.4 84.6±5.5 82.4±30.2 0.675
TG, mg/dL 155.0 (132.0-180.0) 139.5 (102.5-197.5) 135.0 (89.8-214.5) 0.671
Cr, mg/dL 1.0 (0.8-1.3) 1.0 (0.8-1.2) 1.0 (0.8-1.4) 0.786
AST, U/L 20.0 (15.0-27.0) 20.0 (16.0-30.0) 19.0 (14.8-24.3) 0.456
ALT, U/L 21.0 (15.0-31.0) 21.0 (16.0-29.0) 21.0 (14.8-33.5) 0.930
C-peptide, fasting, ng/mL (n=62) 2.2 (1.0-3.4) 2.1 (1.1-3.3) 2.2 (1.0-3.5) 0.797
C-peptide, postprandial, ng/mL (n=62) 4.2 (2.5-6.0) 4.0 (2.5-5.6) 4.3 (2.4-6.1) 0.844
ΔC-peptide (increment), ng/mL (n=62) 1.9 (1.1-3.0) 1.9 (1.1-3.0) 2.0 (1.0-3.1) 0.917
Incline of ΔC-peptide (n=62) 1.0 (0.6-1.9) 1.0 (0.5-1.9) 1.1 (0.6-2.2) 0.749
OAD profiles
Glimepiride, mg (n=59) 2.9±1.1 3.2±1.1 2.7±1.1 0.326
Metformin, mg (n=60) 1,000 (1,000-1,700) 1,000 (1,000-1,700) 1,000 (1,000-1,700) 0.954
Pioglitazone, mg (n=4) 15.0 (15.0-15.0) 15.0 (15.0-15.0) 15.0 (15.0-15.0)
Insulin doses
Glargine, unit  26.2±11.2 26.6±11.9 25.8±10.8 0.560
Glulisine, unit 5.0 (4.0-6.0) 5.0 (4.0-6.0) 5.0 (4.0-6.0) 0.287
Values are presented as mean±standard deviation or median (interquartile range). 
BMI, body mass index; A1c, glycated hemoglobin; GA, glycated albumin; AC, fasting glucose; PC, postprandial glucose; HDL-C, high density 
lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; TG, triglycerides; Cr, creatinine; AST, aspartate aminotransferase; ALT, ala-
nine aminotransferase; OAD, oral anti-diabetic drug.233
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were 63.2±9.8 and 14.8±9.4 years, respectively. Body mass in-
dex (BMI) was 25.6±4.0 kg/m
2. The initial levels of A1c, GA, 
AC, and 2 hour PC after a main meal were as follows: 8.5% 
(8.0% to 9.6%), 25.2±7.6%, 129.5±54.3 mg/dL, and 257.3± 
85.7 mg/dL, respectively. Forty-seven subjects used sulfonyl-
urea with a dose of 2.9±1.1 mg glimepiride. The average doses 
of glargine and glulisine were 26.2±11.2 and 5.0 units (4.0 to 
6.0 units), respectively.
  Patients were classified into two groups according to A1c 
change after 6 months of treatment (Group I <0.5%, n=37; 
Group II ≥0.5%, n=50). The distributions of gender and BMI 
among subjects were relatively even. There were no significant 
differences in AC, PC, Cr, AST, ALT levels, lipid profiles, and 
doses of medications including glimepiride, metformin, 
glargine, and glulisine. When comparing to Group I, the pa-
tients in Group II were older (P=0.021) and had longer dura-
tion of diabetes (P=0.01). Group II had more subjects with 
higher levels of A1c and GA (P<0.001 and P=0.015, respec-
tively) than Group I. With respect to insulin secretory function 
of beta cells, C-peptide increment and incline of ΔC-peptide 
Table 2. Changes in glycemic profiles and drug dose during the study period
Parameter At initiation After 3 mo After 6 mo P value (Basal vs. 3 mo/vs. 6 mo)
A1c, % 8.5 (8.0-9.6) 8.0 (7.5-8.6) 7.8 (7.4-8.5) <0.001/<0.001
Group I 8.0 (7.8-8.3) 8.1 (7.6-8.6) 8.2 (7.7-8.9) 0.536/0.367
Group II 9.0 (8.3-10.1) 7.9 (7.3-8.5) 7.6 (7.1-8.3) <0.001/<0.001
GA, % (n=66) 25.2±7.6 25.2±29.9 22.8±23.1 0.760/<0.001
Group I 22.5±7.2 29.0±44.2 21.0±6.3 0.360/<0.001
Group II 27.1±7.3 22.0±5.3 19.7±4.4 <0.001/<0.001
AC, mg/dL 126.8±46.1 119.4 ± 38.6 123.3±43.4 0.219/0.207
Group I 130.8±67.9 131.6±39.6 128.0±48.6 0.417/0.735
Group II 128.5±42.2 110.0±35.5 119.8±39.1 0.014/0.165
PC, mg/dL 256.1±74.3 203.4±72.8 209.6±80.5  <0.001/<0.001
Group I 264.2±106.2 217.2±73.3 239.7±83.2 0.019/0.140
Group II 252.2±67.6 205.6±83.3 188.6±71.9 <0.001/<0.001
Glargine, units 26.2±11.2 25.9±10.8 27.2±12.4 0.516/0.105
Group I 26.6±11.9 25.5±11.1 28.9±13.8 0.506/0.036
Group II 25.8±10.8 26.2±10.8 26.3±11.2 0.903/0.823
Glulisine, units 5.0±1.0 6.2±2.3 6.4±2.4 <0.001/<0.001
Group I 4.9±0.9 6.5±2.7 6.8±2.5 0.004/<0.001
Group II 5.0±1.1 6.0±2.0 6.1±2.3 0.002/0.007
Glimepiride, mg 2.9±1.1 3.0±1.1 3.0±1.1 0.660/1.0
Group I 3.2±1.1 3.1±1.2 3.1±1.1 0.317/0.317
Group II 2.7±1.1 2.8±1.1 3.0±1.2 0.157/0.083
Metformin, mg 1,000 (1,000-1,700) 1,000 (1,000-1,700) 1,000 (1,000-1,700) 1.000/0.109
Group I 1,000 (1,000-1,700) 1,000 (1,000-1,700) 1,000 (1,000-1,700) 1.000/0.317
Group II 1,000 (1,000-1,700) 1,000 (1,000-1,700) 1,000 (1,000-1,700) 1.000/0.180
No. of hypoglycemic events 8
Group I 3
Group II 5
Values are presented as mean±standard deviation or median (interquartile range). P value <0.025 was considered to be significant when com-
paring values at baseline with values after 3 months or 6 months by paired t-tests or Wilcoxon signed rank tests with the Bonferroni procedure 
for multiple comparisons. 
A1c, glycated hemoglobin; GA, glycated albumin; AC, fasting glucose; PC, postprandial glucose.234
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levels were not significantly different between the two groups.
Glycemic control with basal plus regimen at 3 and 6 
months
After treatment with the basal plus regimen, glucose parame-
ters including A1c, GA, AC, and PC were improved in all sub-
jects (Table 2). A1c was significantly decreased by 0.8±0.1% 
(P<0.001) at 3 months, but there was no significant change in 
GA. After 6 months, A1c and GA were improved by 0.8±0.1% 
(P<0.001) and 5.2±0.7% (P<0.001) in all patients, respective-
ly (Fig. 1). PC levels were significantly decreased 52.8±9.4 mg/
dL (P<0.001) at 3 months, and 48.7±10.3 mg/dL (P<0.001) at 
6 months after initiating the basal plus regimen, respectively. 
However, AC levels were only slightly decreased by 7.5±5.9 
mg/dL (P=0.208) and 6.6±5.2 mg/dL (P=0.205) at 3 and 6 
months, respectively, which were not statistically significant. 
  Group II showed significant improvement in glycemic con-
trol in comparison to Group I. After the first 3 months of treat-
ment, A1c was decreased by 1.2±0.1% and GA showed a re-
duction of 4.9±5.7% in Group II (both P<0.001). However, 
there were no significant differences in A1c and GA among 
subjects in Group I. At 6 months, A1c increased by 0.1±0.1% 
in Group I (P=0.234), while decreasing by 1.5±0.1% (P<
0.001) in Group II. GA decreased by 1.9±0.4% (P<0.001) in 
Group I and by 7.3±1.0% (P<0.001) in Group II after 6 months 
of treatment. Compared to the glucose levels at baseline, there 
were no significant differences in AC and PC in Group I. 
However, in Group II, PC level had significantly decreased 
during the study period (52.9±13.0 mg/dL, 64.3±12.0 mg/dL 
at 3 and 6 months, respectively, both, P<0.001). Hypoglycemic 
events with minor episodes were reported in 8 patients (9.2%) 
and no severe hypoglycemic events occurred during the study 
period.
Independent parameters to achieve better glycemic control
In order to investigate the independent variables that were 
able to predict the likelihood of A1c reduction with the basal 
plus regimen in uncontrolled diabetic subjects currently on 
basal insulin-based combination of OADs, multiple logistic 
regression analyses were performed. The authors included 
clinically important conventional variables (BMI, initial dose 
of glargine, glulisine, glimepiride, and metformin) and estab-
lished the parameters of age, duration of diabetes, and A1c 
which were significantly different between the two groups based 
on the results of Table 1 as independent factors. As a result, old 
age (odds ratio [OR], 1.25; 95% confidence interval [CI], 1.02 
to 1.55), high initial A1c (OR, 22.21; 95% CI, 2.44 to 201.78), 
and low doses of initial glargine (OR, 0.85; 95% CI, 0.76 to 0.99), 
and glimepiride (OR, 0.23; 95% CI, 0.06 to 0.93) were found to 
be independently associated with an A1c reduction of more 
than 0.5% after initiating the basal plus regimen (Fig. 2).
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Fig. 1. Glucose-lowering effect of basal bolus regimen during 
6 months. (A) Changes in glycated hemoglobin (A1c) during 
6 months of treatment between Group I and Group II. (B) 
Changes in glycated albumin (GA) during 6 months of treat-
ment between Group I and Group II.
Fig. 2. Multiple logistic regression models for the variables in-
dependently associated with better response to basal plus regi-
men in patients. The reference group for calculation of the OR 
was Group I. OR, odds ratio; CI, confidence interval; A1c, gly-
cated hemoglobin; DM, diabetes mellitus; BMI, body mass in-
dex.
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DISCUSSION
Little controversy remains regarding early intensive glycemic 
control with basal insulin-based combination of OADs or 
short-acting insulin to prevent or delay diabetic complications 
[1,3,12]. However, when, how, and in whom to initiate insulin 
therapy are still subjects of debate. Accordingly, initiation of 
insulin therapy has been dependent on the factors of A1c, fast-
ing glucose, postprandial glucose level, co-morbidity, patient 
age and remaining pancreas insulin secretory function [13]. 
  Concerning how and in whom to initiate insulin, no docu-
mented data is currently available regarding the effects of the 
addition of rapid-acting insulin analogue to basal insulin (bas-
al plus or bolus regimen) in Korean patients with T2DM. Al-
though numerous studies have reported that timely initiation 
of single-dose basal insulin treatment is a convenient, effective, 
and recommended strategy [4], basal insulin-based regimen 
combined with OADs tends to fail in achieving glycemic goals 
as time passes, because of the natural course of decline in en-
dogenous β-cell function [5,14]. Adding injections of rapid-
acting insulin before a meal is physiologically reasonable to be 
effective in limiting a high glycemic surge after food intake. 
With respect to the frequency of rapid-acting insulin injec-
tions, multiple injections before meals are logical and expected 
to control glycemic levels within a non-diabetic range. How-
ever, due to discomfort and fear of hypoglycemia, patients 
were reluctant to apply multiple administrations of insulin 
[15,16]. Furthermore, Zambanini et al. [17] reported that in-
creased injection frequency may induce anxiety and injection 
avoidance. In this regard, a single injection of rapid-acting in-
sulin is one alternative for patients with poorly controlled 
T2DM. Davidson et al. [10] also reported the effects of one-
time or multiple injections of preprandial rapid-acting insulin 
on patients with secondary failure of basal insulin. They found 
that A1c reductions in patients given single daily injections 
(0.44%) were not inferior to twice (0.36%) or thrice (0.43%) 
daily injections.
  Based on the metabolic characteristics of T2DM in the Ko-
rean population and the natural decline of innate β-cell func-
tion [7,8], we hypothesized that earlier implementation of the 
basal plus regimen would be more likely to attain and sustain 
optimal glycemic targets. Attention was focused on the antici-
pated reduction of glucose levels in subjects following this reg-
imen and investigating predictive characteristics of patients 
who responded satisfactorily to the basal plus regimen after 
failure of the basal insulin therapy.
  The present clinical study with poorly controlled subjects 
who previously were on a basal insulin therapy demonstrated 
two main findings: 1) implementation of a single preprandial 
injection of glulisine at the main meal in subjects with basal 
insulin failure was effective in lowering A1c, with a reduction 
of 0.8±0.1% after 6 months of administration; and 2) elderly 
patients with poorly controlled T2DM who had used a smaller 
amount of glargine or glimepiride showed significant improve-
ments in A1c with the basal plus regimen. 
  Significant reductions of A1c at 3 and 6 months (both 0.8± 
0.1%) were observed in all subjects. After initiation of the bas-
al plus regimen, PC levels were significantly decreased in pa-
tients of Group II, but not Group I. According to the correla-
tion analysis, the reduction of A1c after 6 months of therapy 
was significantly associated with a decrease in PC levels after 6 
months (r=0.254, P=0.021), but not with changes in AC (r=
0.054, P=0.682). The result indicates the addition of glulisine 
may contribute to a reduction of A1c by lowering the glycemic 
surge after a meal. 
  During the 6 months of the basal plus regimen, 12 patients 
(13.8%) achieved an A1c lower than 7% in our study popula-
tion. Similar to Group II, subjects who attained an optimal 
glycemic target of A1c <7% were significantly older than sub-
jects with A1c ≥7% (subjects with A1c <7% vs. subjects with 
A1c ≥7%; 68.2±9.8 years vs. 62.2±10.1 years, P=0.029). 
However, they had lower levels of A1c at baseline comparing 
to subjects with A1c ≥7% (8.1±0.4% vs. 9.0±1.2%, P=0.012).
  The characteristics of subjects with significant reduction of 
A1c were a high initial value of A1c (>9.0%), old age (>65 
years), and low levels of glargine (<20 units) and glimepiride 
(<4 mg). The results suggest the implementation of rapid-act-
ing insulin at a deteriorated stage, due to gradual deterioration 
of β-cell secretory function by increased glimepiride, contrib-
utes to low efficacy in reduction of A1c.
  The present study has several limitations, which should be 
complemented by further investigation. First, the number of 
study subjects was relatively small, and information regarding 
patients’ compliance with medication, life style modification 
and factors related to adverse effects of insulin including weight 
gain, was uncollectable because this was a retrospective study. 
Second, the analysis of clinical data was conducted over a rela-
tively short study period. As a result, our goal of glycemic con-
trol was lower (A1c reduction >0.5%) than other studies (A1c 
reduction >1%). In addition, because the study population 236
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consisted of poorly controlled Korean patients who had a lon-
ger duration of diabetes (>10 years) and predominantly fea-
tured an insulin secretory defect over insulin resistance, the 
results may not be applicable to other ethnic groups with 
T2DM, especially when the major etiologic factor is insulin 
resistance. Therefore, the present findings should be interpret-
ed with caution. However, this is the first clinical study to in-
vestigate the glucose-lowering efficacy and its implications of 
the basal plus regimen for Korean patients with T2DM. 
  In conclusion, the data from the present study showed initi-
ation of a basal plus regimen may be effective in lowering glu-
cose levels of subjects with old age, high initial A1c, and a his-
tory of using smaller amounts of glargine or glimepiride. Fur-
ther studies on the clinical efficiency and safety of the basal plus 
regimens for type 2 diabetic patients will make this study’s ob-
servations useful in the clinical setting.
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